248
Articles Count
1267
Viewing Count
Elise Mak

A China observer

Legend Biotech's BCMA-targeted CAR-T cell therapy ...
Elise Mak · 22 hours ago
Legend Biotech's Carvykti has been granted conditional marketing authorization by the European Commission for the treatment of adults with relapsed and refractory multiple myeloma. More news from HemaCell, GSK, Gracell, Adagene.
Further information
News
Junshi shares more data of COVID-19 pill versus Pa...
Elise Mak · 2 days ago
Junshi Biosciences has shared more Phase III data of VV116, its COVID-19 oral drug, versus Pfizer's Paxlovid and said the study reached its primary endpoint and secondary efficacy endpoint. More news from Wuxi Biologics, CASI Pharma, Hengrui.
Further information
News
GenEditBio closes angel and series pre-A rounds to...
Elise Mak · 3 days ago
Beijing-based GenEditBio has raised dozens of millions of U.S. dollars in angel and Series pre-A funding to develop next-generation gene-editing tools and advance its pipeline. More news from Henlius.
Further information
News
Junshi's COVID-19 tablet meets primary endpoint in...
Elise Mak · 3 days ago
Shanghai Junshi Biosciences' VV116 tablet, an oral nucleoside analog anti-SARS-CoV-2 drug, reached its primary endpoint in a phase III registrational clinical study versus Pfizer's Paxlovid for early treatment of mild to moderate COVID-19. More news from Sinogen, Scindy, WayShine, StarMab
Further information
News
China expands use of Novartis drug Promacta to tre...
Elise Mak · 4 days ago
The NMPA has approved an expanded use for Novartis' Promacta to treat children aged between 6 and 11 with chronic ITP who have had an insufficient response to glucocorticoids and immunoglobulins.
Further information
News
China grants market exclusivity to pediatric and o...
Elise Mak · 5 days ago
China’s drug regulators are accelerating the development pathway of pediatric and orphan drugs through revised regulations. Biotech companies that focus on developing these drugs will be rewarded with market exclusivity.
Further information
Regulatory
Roche China Accelerator to aid nine local biotech ...
Elise Mak · 7 days ago
A year after its launch in Shanghai, Roche China Accelerator said it has identified nine local innovative drugmakers to join efforts with the pharma giant. More news from VerImmune, U-Synbio, Hansoh, ACEA Pharma, CANSino, Bayer.
Further information
News
Hengrui launches Luzsana to bring drugs to North A...
Elise Mak · 8 days ago
Chinese pharma giant Hengrui Pharma has launched a new company named Luzsana Biotechnology to co-develop medicines and commercialize them in North America, Europe and Japan. More news from Meton Pharma, CTTQ, Junshi.
Further information
News
Laekna Therapeutics raises $61 Million in series D...
Elise Mak · 9 days ago
Laekna Therapeutics, which is developing an AKT kinase inhibitor afuresertib and a CYP17/CYP11B2 dual inhibitor, said it closed a $61 million Series D round to accelerate the clinical development of these two drug candidates. More news from Senlang, CStone, Simcere.
Further information
News
Luye Pharma's biotech arm Boan seeks IPO in Hong K...
Elise Mak · 10 days ago
Shandong Boan Biotechnology, established in 2013 as a subsidiary of Luye Pharma Group, is seeking an IPO in Hong Kong with support from UBS and Essence International to keep advancing its biological drug candidates. More news from MingMed, Immune-Onc, Sinopharm.
Further information
News
READ MORE

Personal Information

Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement